CANY
DNLI icon

Caxton Associates (New York)’s Denali Therapeutics DNLI Stock Holding History

Caxton Associates (New York)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-134,047
Closed -$2.77M – 399
2018
Q4 		$2.77M Buy
134,047
+30,000
+29% +$544K 0.44% 30
2018
Q3 		$2.26M Buy
+104,047
New +$1.72M 0.16% 120

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Caxton Associates (New York)'s DNLI Position: Q1 2019 in Review

Caxton Associates (New York) sold out of Denali Therapeutics (DNLI) in Q1 2019, closing a stake of 134,047 shares — an estimated $2.77M sold.

Caxton Associates (New York) first reported a position in DNLI in Q3 2018 and held it in 2 quarters. The position peaked at $2.77M in Q4 2018. 114 funds tracked by Wall St. Rank hold DNLI as of Q1 2019.

  • Caxton Associates (New York) reported no remaining Denali Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 134,047 Denali Therapeutics shares in Q1 2019, an estimated $2.77M.
  • Caxton Associates (New York) first reported a position in Denali Therapeutics in Q3 2018 and held it in 2 quarters.
  • Caxton Associates (New York)'s Denali Therapeutics position peaked at $2.77M in Q4 2018.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2019.

Based on Caxton Associates (New York)'s 13F filing for Q1 2019, filed 15 May 2019.